# Marksans Pharma Limited (MARKSANS)

> MARKSANS closed at ₹306.20 on 30 Oct 2026, trailing P/E 26.9, market cap ₹13,876 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Marksans Pharma Limited (NSE: MARKSANS) closed at ₹306.20 on 30 Oct 2026, +72.9% over one year, against a 52-week range of ₹155.00 – ₹350.95.

In the quarter ended 30 Jun 2026 (consolidated, filed 12 Aug 2026) it reported revenue of ₹841 cr and net profit of ₹157 cr, a 18.7% net margin; revenue grew 35.6% and profit grew 169.7% year on year.

On four consecutive filed quarters its trailing P/E is 26.9; since 19 May 2025 its own P/E has ranged from 25.0 to 313.8 (median 191.9), and today's reading is higher than 8% of those 359 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 20.8%, ROCE 25.6%, debt-to-equity 0.01, Piotroski F-score 4 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 68% of 63 sector peers; PBT margin higher than 71% of 63 sector peers; ROE higher than 78% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹306.20 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -9.2% / +61.0% / +72.9% |
| 52-week low – high | ₹155.00 – ₹350.95 |
| Market capitalisation | ₹13,876 cr |
| Trailing P/E | 26.9 |
| Price / book | 4.59 |
| EV / EBITDA | 16.3 |
| Earnings yield | 3.7% |
| TTM EPS | ₹11.40 |
| TTM net profit | ₹517 cr |
| Quarter revenue | ₹841 cr |
| Quarter net profit | ₹157 cr |
| Net margin | 18.7% |
| Revenue growth (YoY) | +35.6% |
| Profit growth (YoY) | +169.7% |
| Return on equity | 20.8% |
| ROCE | 25.6% |
| Debt / equity | 0.01 |
| Current ratio | 5.17 |
| Free cash flow | ₹328 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹58.5 cr |

## Questions

### What is the P/E ratio of Marksans Pharma Limited?

Marksans Pharma Limited's trailing P/E is 26.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 19 May 2025 its P/E has ranged 25.0–313.8.

### What were Marksans Pharma Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Marksans Pharma Limited reported revenue of ₹841 cr and net profit of ₹157 cr (consolidated), filed with the exchange on 12 Aug 2026.

### What is Marksans Pharma Limited's ROE?

Return on equity is 20.8% based on the balance sheet dated 31 Mar 2026.

### Does Marksans Pharma Limited have debt?

Debt-to-equity is 0.01 on the balance sheet dated 31 Mar 2026.

### What is MARKSANS's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, MARKSANS traded between ₹155.00 and ₹350.95.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/MARKSANS

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._